Bank of America is investing heavily in employee healthcare, with Chief Executive Officer Brian Moynihan revealing that the bank now spends more than $250 million each year covering GLP-1 weight-loss medications for its workforce.

The spending reflects the growing adoption of blockbuster obesity and diabetes treatments such as Ozempic, Wegovy, and Zepbound, which have become increasingly common in employer-sponsored health plans despite their high annual costs.

GLP-1 Spending Becomes a Major Healthcare Expense

Bank of America now spends more than $2 billion annually on healthcare benefits for its approximately 211,000 employees. GLP-1 medications account for roughly 13% of that total, highlighting how rapidly demand for the drugs has expanded over the past several years.

Moynihan noted that the bank’s annual spending on GLP-1 therapies has risen from virtually zero just four to five years ago to more than $250 million today.

Despite the higher costs, management believes the investment is delivering meaningful health improvements for employees.

Long-Term Health Benefits Drive Investment Strategy

According to Moynihan, Bank of America views access to GLP-1 medications as a long-term investment in workforce health rather than simply an additional employee benefit.

The bank combines prescription coverage with health coaching programs that help employees monitor weight loss and adopt healthier lifestyles. Management also pointed to growing clinical evidence showing that GLP-1 therapies may reduce the risk of heart attacks, strokes, heart failure, and other cardiovascular conditions in addition to supporting significant weight loss.

While some employees may leave the company before long-term healthcare savings are fully realized, Moynihan said improving employee well-being remains a priority.

The bank is also negotiating aggressively with pharmaceutical manufacturers and pharmacy benefit managers in an effort to reduce prescription costs.

Employers Continue Evaluating GLP-1 Coverage

Bank of America’s experience reflects a broader trend among U.S. employers as demand for GLP-1 medications continues to grow.

According to a recent survey by the International Foundation of Employee Benefit Plans, 36% of employers now provide coverage for GLP-1 drugs for both diabetes treatment and weight management. The survey found these medications represented 11.4% of employer health claims in 2026, compared with 6.9% in 2023, underscoring their rapidly increasing financial impact.

Drug manufacturers, including Eli Lilly and Novo Nordisk, continue expanding employer programs aimed at improving access through discounted pricing and broader insurance coverage.

Meanwhile, a recent Gallup survey found that approximately 11% of U.S. adults now use a GLP-1 medication for weight loss, up from just 3% in 2024.

Benefits Come With Medical Considerations

Although GLP-1 therapies have demonstrated substantial benefits for weight management and cardiovascular health, physicians continue to monitor potential side effects associated with rapid weight loss.

Among the more recent cosmetic concerns is “temporal hollowing,” commonly associated with the broader phenomenon known as “Ozempic face,” where facial fat loss can create a more aged appearance. Medical experts note that gradual weight loss under physician supervision may help reduce these effects, while cosmetic procedures remain available for patients seeking treatment.

Healthcare providers continue to emphasize that GLP-1 medications should be used under medical supervision with individualized treatment plans.

Closing Insights

Bank of America’s growing investment in GLP-1 medications highlights how obesity treatments are becoming a significant component of employer-sponsored healthcare. While the drugs have substantially increased healthcare spending, the bank believes improved employee wellness and lower long-term medical risks justify the expense. As clinical evidence continues to expand and employers negotiate lower pricing, GLP-1 therapies are likely to play an increasingly important role in corporate healthcare strategies across the United States.